At a glance
ClinicalIndex Comparison Record- ✓Relapsed or refractory Hodgkin lymphoma after ABVD with high-risk definition
- ✓Age 18 to 90 years
- ✓Informed consent signed
- ✕Voluntary withdrawal from study
- ✕Grade 3 or 4 toxicity per INH scale
- ✕Loss of follow-up
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT05595447Phase 3RecruitingUpdate OverdueUpdated 15mo ago · Completion was 8mo agoRescue With Brentuximab Plus PD-1 Blockade Followed by Autotransplantation and Consolidation With Brentuximab Plus PD-1 Blockade in Patients With Relapsed/Refractory Hodgkin Lymphoma: Exploratory Single-arm Analysis
In Brief
A Phase 3 clinical trial evaluating Brentuximab Vedotin 50 MG [Adcetris] for Hodgkin Lymphoma and 2 related conditions. Currently recruiting, targeting 20 participants across 1 site.
Signals
Detailed Summary
The choice of the best second-line therapy in patients with high LH R/R risk, it is a niche of knowledge not covered at the moment, especially the role of Brentuximab (BV) plus PD-1 blockade and auto-HSCT. What is the progression-free survival and rate of metabolic responses complete in patients with high-risk R/R HL with the treatment strategy: BV+ PD-1 blockade consolidation with Auto-HSCT and maintenance with BV + PD-blockade 1?
Study Details
Timeline
Interventions
Brentuximab plus blocked PD-1 plus ASCT plus maintenance Brentuximab plus blocked PD-1